Clinical Trials
204 trialsFirst-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
Henan Cancer Hospital
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Henan Cancer Hospital
Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer Patients
Coordinación de Investigación en Salud, Mexico
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Henan Cancer Hospital
Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.
Henan Cancer Hospital
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Bisantrene Combination for Resistant AML
Sheba Medical Center
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Fujian Cancer Hospital
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
National Cancer Center, Korea
MorphineGEL
Instituto Nacional de Cancer, Brazil
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Henan Cancer Hospital
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
Henan Cancer Hospital
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Henan Cancer Hospital
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
Henan Cancer Hospital
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Fujian Cancer Hospital
MSI-H/dMMR
Henan Cancer Hospital
DAP-Her-01
Henan Cancer Hospital
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
CKD-702 Plus Irinotecan in Gastric Cancer
National Cancer Center, Korea
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
Fujian Cancer Hospital
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Fujian Cancer Hospital
Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
Henan Cancer Hospital
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Fujian Cancer Hospital
EGFR-targeted Therapy for Gastric Cancer
National Cancer Center, Korea
Vactosertib and Durvalumab in Gastric Cancer
National Cancer Center, Korea
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Fujian Cancer Hospital
Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer
City Clinical Oncology Hospital No 1
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Fujian Cancer Hospital
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Tel-Aviv Sourasky Medical Center
ERLO-XIB
Tata Memorial Hospital
To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
Fujian Cancer Hospital
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART
Tel-Aviv Sourasky Medical Center
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
National Cancer Center, Korea
Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
National Cancer Center, Korea
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
National Cancer Center, Korea
AvaTa
National Cancer Center, Korea
Atezolizumab
National Cancer Center, Korea
Study of Lorlatinib in ROS1 Rearranged NSCLC
National Cancer Center, Korea
Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
National Cancer Center, Korea
REPAN
King Abdullah Medical City
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
Henan Cancer Hospital
SPACE
Kirby Institute
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Henan Cancer Hospital
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Fujian Cancer Hospital